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D
espite the well-known inﬂuence of
maternal glucose on infant birth
weight (BW), the prevalence of
large for gestational age (LGA) infants
($90th percentile for age) has been in-
creasing steadily over decades, particu-
larly in pregnancies complicated by
pregestationalorgestationaldiabetesmel-
litus (1). Although the overall prevalence
ofmacrosomia(BW$4,000g)is17–29%
in women with untreated gestational di-
abetes, the majority of macrosomic in-
fants are born to women with obesity
but no gestational diabetes (2,3). More-
over, epidemiologic data show that a
higher BW is associated with higher BMI
and glucose intolerance later in life (4,5),
suggesting life-long metabolic implica-
tions for offspring.
Recent data from the Hyperglycemia
andAdversePregnancyOutcomes(HAPO)
study suggested that concentrations of
maternalglucosebelowthepreviouslyac-
cepted diagnostic thresholds for gesta-
tional diabetes are predictive of LGA
and fetal hyperinsulinemia (6). On the
basis of this landmark study, the Inter-
national Association of Diabetes in Preg-
nancy Study Group and the American
Diabetes Association (ADA) recommended
new lower diagnostic criteria for gesta-
tional diabetes (7,8). However, a signiﬁ-
cant number of women with gestational
diabetes whose glucose values are within
the current targeted therapeutic ranges
deliver macrosomic infants (9). Although
glucose plays a major role in fetal growth,
this paradox underscores the likely role
of other nutrients in fetal growth, but
also the need to critically reexamine our
deﬁnition of “normal” maternal patterns
of glycemia and the effects on fetal
growth. The new diagnostic criteria rec-
ommended by the International Associa-
tion of Diabetes in Pregnancy Study
Group and ADA are expected to increase
the prevalence of gestational diabetes to
18%.Thus,treatmenttargetsmayneedto
be reevaluated.
Historically, the treatment goal in
pregnancies complicated by diabetes has
been to mimic patterns of glycemia in
normal pregnancy (1). Although the
HAPOstudy betterdeﬁned abnormalgly-
cemic thresholds for the diagnosis of ges-
tational diabetes based on fetal outcomes,
thecurrentclinicalguidelinesfordeﬁning
treatment targets (10–13) are less rigor-
ous given that optimal therapeutic targets
remain untested in randomized trials
(14). Further, there has been a reluctance
to compare descriptive data in “normal”
pregnant women because of the difﬁculty
of comparing major differences in study
design, patient characteristics, and meth-
odology. Nevertheless, ;5 decades of
researchhave helped deﬁne“normal”ma-
ternal glucose metabolism. The intent of
this review is to offer the clinician 1)a
clear graphic representation of available
glucose data collected in “normal” preg-
nancy (i.e., a pooled analysis of weighted
averages across 12 studies involving non-
obese patients); 2) a full discussion of
study methodologies and limitations;
and3) aproposalof moreaggressive ther-
apeutic targets that may be prospectively
tested for the prevention of fetal macro-
somia.
RESEARCH DESIGN AND
METHODS
Literature search strategy and
inclusion of evidence
PubMed was searched broadly using key-
words such as pregnancy, glycemia, glu-
cose, diurnal patterns, and gestational
diabetes. Reference lists in review papers,
original manuscripts, and expert reports
were compared with ﬁndings in PubMed.
Data were included if they provided in-
formation on glycemic patterns in normal
pregnancy, excluding type 1 or 2 diabetes
or gestational diabetes. Patterns needed to
have been established using diurnal pro-
ﬁling techniques such as hospital admis-
sion with frequent blood sampling, serial
measures of self-monitored blood glu-
cose (SMBG), or a continuous glucose
monitoring system (CGMS). The pat-
terns of glycemia required characteriza-
tion during controlled or ad libitum
dietary intake to include the effect of
incretin hormones and the enteroinsular
axis (15). Thus, investigations using aglu-
cose challenge or glucose infusion were
not considered.
Graphic portrayal of data and
weighted averages
Exactdatawereplottedasreportedintext
or tables by the original authors. When
datawereonlyshowninﬁgures,themean
and variance were taken from the graphs.
In some cases, complete patterns of gly-
cemia were not reported between meals.
For graphic purposes, if a premeal value
wasnotreported,the24-hmeanwasused
as the between-meal glucose concentra-
tion. In the graphs, postprandial (PP)
spikes are 1 h (60–70 min) and 2 h
after a meal as reported.
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Reviews/Commentaries/ADA Statements
REVIEWBecause test statistics were not uni-
formly reported and methodologies for
measuring glucose concentrations were
variable, a formal meta-analysis was not
possible. Thus, this is a pooled analysis of
12 studies that met our inclusion criteria.
Weighted means and SDs were calculated
as the product of the mean reported value
and samplesize for each study.The sumof
the products across studies was then
calculatedanddividedbythetotalnumber
of study participants. In addition, mean
1- and 2-h PP glucose concentrations were
calculated across three meals (breakfast,
lunch, and dinner). Data are presented as
weighted mean 6 SD.
RESULTS—Twelve studies met the cri-
teria for inclusion with a total of 255
pregnant women with normal weight and
glucose tolerance (Table 1). Table 2 re-
ports data from the included studies,
and Fig. 1A graphically depicts the pat-
terns of glycemia. The mean gestational
week of study was 33.8 6 2.3 weeks
(range 24–40.8 6 0.09–8.1 weeks). Most
of the women had a BMI ,25 kg/m
2, al-
though prepregnancy BMI versus BMI at
the time of study was variably reported
and speciﬁc BMI ranges were often unre-
ported. On average, fasting blood glucose
(FBG) was 70.9 6 8m g / d L( n = 195)
(Table 2). The weighted mean pattern of
glycemia (including FBG, 1- and 2-h PP,
and 24-h mean glucose) is shown in
Fig. 1B.
In Table 2, the data from ﬁve inpa-
tient studies (16–20), one SMBG study
(21), and six CGMS studies (22–27) are
reported. The inpatient studies were con-
ducted decades earlier than the CGMS
studies, and women were admitted to a
metabolic ward. The average FBG con-
centrations were similar across all of the
studies, with the exception of the single
SMBG study (21) (Fig. 1A). Across stud-
ies, the 24-h mean glucose ranged from
77.4 6 4.7 to 97 6 9 mg/dL. The single
SMBG study reported the lowest glucose
concentrations compared with all other
studies. However, by excluding these
data, the weighted means changed mini-
mally and these data were included be-
cause of the structured study design and
controlledvariance.One-hPPglucoseex-
cursions were higher in the inpatient
studies compared with the SMBG and
CGMS studies (115.2 6 13.4 compared
with101.863.8and110.5617.7mg/dL,
respectively). However, 2-h PP glucose
concentrations were similar for inpa-
tient and CGMS studies (103 6 13 vs.
102.2 6 12.2 mg/dL, respectively) but
were lower in the SMBG study (92.6 6
4.7 mg/dL). With all studies included,
the average 1- and 2-h PP glucose concen-
trations across meals were 108.9 6 12.9
and 99.3 6 10.2 mg/dL, respectively (n =
160–192; Fig. 1B). The 61S Dr a n g e
above the weighted mean for a 1-h PP
was 96.0–121.8 mg/dL, and the 62S D
range was 83.1–134.7 mg/dL. For the
2-h PP target, 61 SD above the weighted
mean ranged from 89.1 to 109.5 mg/dL,
and 62 SDs above the weighted mean
ranged from 78.9 to 119.7 mg/dL. Time
topeakglucoseconcentrationafterameal,
based on the CGMS articles (22,24,25),
was an average of 69.4 6 23.9 min (n =
102).
Review of evidence and discussion
The most compelling ﬁnding from our
review of the available literature is that
glucose concentrations during normal
pregnancy in the absence of obesity are
lower than the current suggested normal
therapeutictargets.AsdepictedinFig.1B,
the weighted mean pattern of glycemia
revealsanFBGof7168mg/dL,followed
by 1- and 2-h PP glucose concentrations
of 109 6 13 and 99 6 10 mg/dL, respec-
tively,anda24-hglucoseof88610mg/dL.
These weighted mean values are appre-
ciably lower than the currently recom-
mended therapeutic targets of #95 mg/dL
for FBG, ,140 and ,120 mg/dL at 1- and
2-h PP, respectively (13). Although HAPO
provided rigorous outcome data to deter-
mine the thresholds appropriate for the
diagnosis of gestational diabetes, there
are a paucity of data on appropriate ther-
apeutictargetsforwomenwithdiabetesor
gestational diabetes. Until prospective
outcome data are generated by examining
the most appropriate therapeutic targets
to minimize both LGA and small for ges-
tational age (SGA) infants (infants ,10th
percentile for gestational age), mimicking
patterns ofnormalglycemiainpregnancy,
in women without obesity, remains a rea-
sonable goal. The data presented would
argue that lower targets be tested in future
prospective trials.
Differences in methodology
There has been a reluctance to compare
data characterizing glycemia in preg-
nancy, largely because of differences in
study design and methodologies. Studies
in women admitted to a hospital have
been criticized because of the highly
controlled nature of the design (28), the
lack of repeated measures throughout
pregnancy,andthesmallnumbersofpar-
ticipants (21). These studies removed
women from the free-living environment,
which changed their physical activity pat-
tern. However, dietary carbohydrate in-
take was controlled and a liberal amount
(190–275g/day)wasadministered(Table
1). The controlled physical activity and
liberal carbohydrate intake may explain,
in part, the somewhat higher PP peaks,
particularly by Phelps et al. (20) (Table 2,
Fig. 1). Nevertheless, the patterns of gly-
cemia across inpatient studies remain re-
markably similar. The CGMS studies may
be criticized for opposite reasons. With
the exception of one study (27), investi-
gations using CGMS tended to poorly
control for the week of pregnancy, with
variance up to 68 weeks reported (22).
This makes glucose concentrations difﬁ-
cult to compare because of the variably
increasing insulin resistance with each
passing week of the third trimester
(29,30). Also, with the one exception
(27),noeffort wasmadetocontroldietary
intake or physical activity. Further, the
methods for interpreting the large volume
of data points generated by CGMS are not
well described in regard to how FBG and
PP values were deﬁned.
There has been further reluctance to
compare data among studies because of
variations in the methodologies used to
measure glucose concentrations. Glucose
is unstable in whole blood, including
capillary blood. Compared with serum
or plasma, glucose concentrations are
11–12% lower in whole blood because
of erythrocyte metabolism of glucose via
glycolysis. Moreover, compared with
plasma, serum glucose concentrations
can decrease ;0.6 mmol/L/h as the result
of glycolysis during sample preparation
(31). Since 1987 (32), glucometers have
been standardized (31) to report plasma-
adjusted glucose values (within 615%)
(33). Current CGMS technology mea-
sures glucose concentrations in intersti-
tial ﬂuid, which are highly correlated
with glucometer-derived plasma-corrected
glucose measures (34,35). Thus, although
capillary and interstitial glucose con-
centrations are not recommended for di-
agnostic purposes (7,33,34), they seem
reliable for determination of glucose
trends (33,34).
On the basis of our detailed review of
the published studies, we think the pooled
studies for our analyses were comparable
according to the following criteria. First,
the inpatient studies reported laboratory-
derived glucose concentrations measured
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or serum (photoelectric) (17) (Table 1).
None used whole blood measurements,
whichwouldhaveproducedlowerglucose
concentrations. Second, the single SMBG
study (21) used a reﬂectance photometry-
based glucometer that reported plasma-
corrected values comparable (,10%
error) to the standard laboratory glucose
oxidase method(36). Thus,the lower glu-
cose concentrations in the SMBG study
(21) cannot be explained by use of this
glucometer. Third, the CGMS interstitial
glucoseconcentrationsarecorrelatedwith
now standardized glucometer-derived,
plasma-corrected glucose measures
(34,35). Therefore, although there is
undoubtedly a degree of variance among
methodologies, it is reasonable to com-
pare the data for therapeutic purposes.
Early descriptive studies of glycemia
in pregnancy
The earliest study of glucose metabolism
in pregnancy revealed that PP glucose con-
centrations were higher despite higher
insulin levels (37), implying a degree of
maternal insulin resistance. These early
observations were conﬁrmed in later
studies (16–18,20,37) (Tables 1 and 2).
Gillmer et al. (16) showed that during
normal pregnancy, mean diurnal glucose
concentrations increased only 4 mg/dL
and rarely exceeded 100 mg/dL. Cousins
etal.(18)demonstratedthatalower24-h
glucose area under the curve could be
explained by relative nocturnal hypogly-
cemia. In addition, third-trimester, 2-h
postmeal glucose excursions were higher
compared with those at 22 to 26 weeks’
gestation.
Studies using SMBG
Parretti et al. (21) published the only
study in which SMBG was used to char-
acterizepatternsofglycemia(51pregnan-
cies) controlling for gestational age.
Women measured their blood glucose
every 2 h throughout the day and night
and ate their meals within deﬁned time
periods. This structured study tried to
approach what had previously been pos-
sible only during hospital admission.
However, glucose concentrations were
far lower than those in any other study
(Table 2, Fig. 1A). Although the glucom-
eter used does not seem to explain the
lower concentrations, it is possible the
womeninthisstudyweremorephysically
active or consumed less simple carbohy-
drates compared with other studies. Fur-
thermore, the women were not blinded
to the glucometer measurements, and it
is possible that they changed their be-
havior on the basis of their SMBG con-
centrations.
Studies using CGMS
The advent of CGMS made it possible to
measure continuous patterns of glycemia
over a 24-h period, rather than hourly.
By using CGMS, it was recognized that
women with gestational diabetes had
occult periods of hyperglycemia not cap-
tured using SMBG (38). Moreover, the
glucose peak occurred 90 min PP (rather
than 70 min) with thetendency to remain
elevatedfor3hwithoutreturningtobase-
line (39). In another CGMS study, obese
pregnant (BMI .27 kg/m
2)w o m e nw e r e
shown to have higher preprandial and PP
glucose, compared with normal-weight
control subjects, and the PP peak was de-
layed 15 min (22). Unexpectedly, these
obese women also had lower nocturnal
glycemia compared with control subjects
(22). In contrast, Porter et al. (23) did not
observe differences in nocturnal glycemia
between women with and without a his-
tory of macrosomia (Table 1). The former
study is the most highly cited study (22)
in support of current clinical practice for
PPglucosemonitoring(13).However,the
week of pregnancy during which CGMS
was worn varied between 21 and 37
weeks of gestation, diet was not con-
trolled (or reported), and the CGMS anal-
ysis of the data was generally not well
described (22). Thus, interpretation of
the data is limited.
Other groups using CGMS have at-
tempted to control sources of variance
(24), but even women with normal preg-
nancies seem to have a wide range of glu-
cose concentrations (Table 1) (26). In the
mostcontrolledCGMSstudytodate(27),
PP blood glucose concentrations in-
creased up to 36 weeks of gestation
despiteaself-reportedconstantcaloricin-
take; macronutrient composition of the
diet was not reported. Because the study
was well controlled for the week of preg-
nancy, this report provides perhaps the
best interpretable data from CGMS yet
published.
In summary, the inpatient studies
were less “real-world,” but the physical
activity and dietary intake were highly
controlled, so they likely best captured
the normal physiology of pregnancy. On
the other hand, the CGMS studies, al-
though less controlled, better depict
free-living conditions. Both types of stud-
ies require careful interpretation but
provide important information. Taken
together, the data reveal a range of glyce-
mia in glucose-tolerant women, yet a re-
markably similar pattern among studies
(Fig. 1A).
Basis for the currently recommended
therapeutic targets
The currentclinical recommendationsfor
treatment targets in pregnancies compli-
cated by diabetes are not uniform inter-
nationally or primarily based on the
studies listed in Table 1. Although the
therapeutic targets were chosen to atten-
uate the risk for fetal macrosomia, they
have never been prospectively tested
compared with lower targets (12,13).
Even when current glucose targets are
achieved in the pregnancy affected by di-
abetes, macrosomia still occurs and in
utero programming may have a lasting
metabolic impact on the offspring
(40,41).
The current therapeutic targets of
#95 mg/dL for FBG, ,140 mg/dL for
1-h PP glucose, and ,120 mg/dL for 2-h
PP glucose (13) were established on the
basis of data from women with pregesta-
tional and gestational diabetes. In 1986,
Willman et al. (42) reported data in 95
women with medication-treated gesta-
tional diabetes (A2 gestational diabetes)
that indicated a mean 24-h blood glucose
concentration .130 mg/dL was associated
with a high risk of fetal macrosomia. In
1992, Combs et al. (43) reported that in
pregnant women with class BthroughRF
diabetes, a 1-h PP target equal to 130
mg/dL during gestational weeks 29–32
suggested a reduction in macrosomia in-
cidence without increasing the incidence
of SGA. Previously, it had been thought
that monitoring preprandial versus PP
glucose concentrations were equally ef-
fective in preventing macrosomia (44).
However, data from women with preges-
tational diabetes (45,46) and later with
gestational diabetes (44) established the
relation between PP glucose and infant
body weight/fetal macrosomia, as well
as other infant outcomes (47). The ran-
domized study of de Veciana et al. in
1995 (44) demonstrated that targeting a
1 - hP Pg l u c o s e( c o m p a r e dw i t hp r e p r a n -
dial) in women with gestational diabetes
was superior in the reduction of macro-
somia incidence. In this study, an FBG
threshold of ,105 mg/dL and a 1-h PP
threshold of ,140 mg/dL were used, but
they were not compared with any other
threshold. In 1998, this evidence was
cited as the basis for 1- and 2-h PP
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Hernandez and Associatesthresholdsof,140and,120mg/dL,re-
spectively (14). As a result, these targets
wereusedinmoststudiespublishedafter
the year 2000 (21,48–50). As recognized
by others (13,51), these cutoffs are not
based on randomized studies of alternate
treatment targets. In the most recent
guidelines from the ADA 5th Interna-
tional Conference on Gestational Diabe-
tes, two studies were cited to support
maintaining the current therapeutic tar-
gets (21,22) without citation of the inpa-
tient (16–20) or other CGMS studies
(23–26).
Although the prevention of macro-
somia is clearly an important target for
therapy during the pregnancy compli-
cated by diabetes, it is equally important
to consider the risk for SGA when testing
lower therapeutic targets. Langer and
Mazze (52) and Langer et al. (53) ob-
served that a range of 87–104 mg/dL for
mean 24-h blood glucose can minimize
both SGA and LGA incidence. It has fur-
ther been observed that overtreatment of
pregnant women with diabetes with in-
sulin can cause SGA (54). However, the
considerations for type 1, type 2, and ges-
tational diabetes may be different. In
long-standing type 1 diabetes, placental
perfusion may be compromised to a vari-
able degree because of abnormal placen-
tation from underlying vascular disease
or hypertension that may limit glucose
availability to the fetus (55). Thus, if glu-
cose concentrations are too low in preg-
nant women with long-standing diabetes
accompanied by vascular disease or pla-
cental insufﬁciency, the glucose gradient
to the fetus may be further compromised.
This is unlikely to be the case with un-
complicated gestational diabetes. It is
also critical to acknowledge that increas-
ing evidence suggests other factors, such
as free fatty acids and triglycerides, are
extremely important in inﬂuencing fetal
growth (56,57) as are prepregnancy BMI
and, to a lesser extent, gestational weight
gain (58). None of the trials that have ex-
amined therapeutic glycemic targets to
prevent macrosomia have controlled for
these signiﬁcant confounders.
Challenge to reconsider current
therapeutic targets
In this critical review and pooled analysis
of 12 studies (n = 255 women), we have
for the ﬁrst time graphically compiled
patterns of glycemia in normal pregnancy
(Fig. 1A and B) and derived weighted
means and SDs for clinical application.
As seen in Table 2 and Fig. 1A, despite
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Patterns of glycemia in normal pregnancythe differences in study design and meth-
odology for measuring glucose, the data
fall into a remarkably similar range. The
weighted average for FBG was 70.9 6 7.8
mg/dL (n = 195), well below the current
therapeutic target of #95 mg/dL (13) and
below the HAPO-based diagnostic
threshold of ,92 mg/dL (7,8). The
weighted average for 1- and 2-h PP glu-
cose concentrations across meals were
108.9 6 12.9 and 99.3 6 10.2 mg/dL,
respectively, also far below the current
targets of ,140 and ,120 mg/dL. Fi-
nally, the weighted mean 24-h glucose
was 88 6 10 mg/dL, on the lower end
of the observed 87–104 mg/dL range
that is thought to minimize SGA and
LGA incidence (52,53).
TheHAPOstudydocumentedamean
FBG of 80.9 mg/dL in .25,000 women
with an average BMI of 28 kg/m
2 and de-
termined that LGA and a cord C-peptide
$90th percentile were 1.75 times higher
atanFBG$92 mg/dL (6). Thus, thereare
strong data to support that this fasting di-
agnosticthresholdmightbeadoptedasan
FBG therapeutic target. However, there
are no equivalent data for PP targets. On
the basis of our pooled analysis, we sug-
gest prospective controlled studies are
needed to test more aggressive therapeu-
tic targets for PP glycemia in pregnancies
affected by diabetes, uncomplicated by
underlying vascular disease, hyperten-
s i o n ,o rs m o k i n g ,a n dc o n t r o l l e df o r
BMI and gestational age. On the basis of
theweightedmeans,the61SDabovethe
weighted mean for a 1-h PP glucose
ranges from 96 to 122 mg/dL and the
62S Dr a n g e sf r o m8 3t o1 3 5m g / d L .
For the 2-h PP target, 61S Da b o v et h e
weighted mean ranges from 89 to 110
mg/dL, and 62 SDs above the weighted
mean ranges from 79 to 119 mg/dL. Al-
though the glucose targets 2 SDs above
the weighted means (135 mg/dL for 1 h
and 119 mg/dL for 2 h) are similar to the
currenttherapeutictargets,itisimportant
to keep in mind that these values are the
high end of the SD range. Thus, if a
woman with gestational diabetes consis-
tently demonstrates a glucose concentra-
tion at or ;135 mg/dL 1 h after a meal,
her average value will signiﬁcantly exceed
the population mean of 110 mg/dL. Al-
though observing that +2 SD values are
helpful for understanding normality in a
population,itispossiblethattargetingthe
mean or the +1 SD range of values will
result in a lower risk of macrosomia
and, more important, excess neonatal ad-
iposity(59).Therefore,wesuggesttesting
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Hernandez and AssociatesPP targets at +1 SD above the calculated
weighted means, 122 and 110 mg/dL
(120 and 110 mg/dL, rounded for clinical
use) for 1 and 2 h, respectively (Fig. 1B), in
womenwithoutsigniﬁcantrisks forplacen-
tal insufﬁciency. We also strongly recom-
mend that recent data supporting a role
for maternal lipids as a signiﬁcant contrib-
utor to excess fetal growth be concurrently
evaluated in such future studies (60).
CONCLUSIONS—The results of 45
years of data characterizing glycemia in
normal pregnancy strongly support the
need for future prospective studies that
speciﬁcally test lower therapeutic PP gly-
cemic targets for gestational diabetes, and
possibly obese patients, to potentially
limit a looming epidemic of fetal macro-
somia.
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